Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antivirals - Microbiotix

Drug Profile

Research programme: antivirals - Microbiotix

Alternative Names: MBX 468; MBX 685; MBX 769S

Latest Information Update: 27 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Microbiotix
  • Developer Microbiotix; University of Michigan
  • Class Antivirals; Cyclopropanes; Purine nucleosides; Small molecules
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C; Human herpesvirus 6 infections; Human herpesvirus 8 infections; Influenza A virus H5N1 subtype
  • Discontinued Epstein-Barr virus infections; Hepatitis B

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Human-herpesvirus-6-infections in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top